Deep Tech Startups
5,885 companies tagged Deep Tech, with their investors and founders.
Overworld develops technology that turns generated images into interactive, inhabitable 3D worlds, and offers its Waypoint model with local and browser-based play options. It provides developer tools for building and exploring these environments.
3 investors
Pale Blue develops and manufactures water-based propulsion systems for small satellites, serving satellite integrators and operators globally. The company aims to enable growth in the space industry by providing essential in-space mobility solutions.
3 investors
Pantheon Design manufactures 3D printers designed for hardware engineers and product developers. The company serves teams building physical products including automotive parts, medical devices, and custom mechatronics systems.
3 investors
Parallel Domain creates synthetic data for autonomous systems development, addressing data generation bottlenecks in the industry. The company serves autonomous vehicle and robotics companies through its PD Replica simulation and synthetic data platform.
3 investors
Parallelz is building a computing architecture and platform that converts existing native mobile apps into native-web apps without code modifications or SDKs, allowing them to run in a browser without installs or app stores. It targets mobile app developers, including in mobile gaming, in the app distribution and discovery space.
3 investors
Paratus Sciences develops first-in-class medicines for cardiometabolic and immune & inflammatory diseases by leveraging evolutionary biology and AI to identify novel drug targets. The company uses biological insights from bats and other evolved organisms to design therapeutic solutions for chronic illness.
3 investors
PassiveLogic develops AI systems for autonomous building control and operations. The company provides a Physical AI stack to autonomously manage building infrastructure, energy consumption, and operations.
3 investors
Passkey operates Locksmith, a computational platform that uses human genetics, biology, and pharmacology to identify synergistic drug combinations from approved and late-stage drugs, allowing existing assets to be repurposed for new indications. The company partners with pharmaceutical firms to map clinic-ready combinations that bypass preclinical development and move directly to human trials, initially targeting complex diseases such as cancer.
3 investors
PentaBind designs programmable aptamers—small RNA/DNA molecules with sub-nanomolar binding affinity—for continuous sensing and diagnostics applications (e.g., monitoring hormones and biomarkers) and targeted therapeutics in oncology and drug delivery. The platform reduces aptamer design cycles from months to ~22 days and delivers application-ready assets rather than just binders.
3 investors
PES Technologies develops a soil health sensor with a consumable design that uses machine learning to analyse soil, aimed at agriculture and sustainable land management. The company is based in the UK and serves the agtech market.
3 investors
Petal is developing an incisionless surgery platform using Millisecond Pulse Histotripsy, a form of focused therapeutic ultrasound that breaks down targeted diseased tissue without incisions, heat, or trauma. The system is designed for patients, clinicians, and hospitals as an alternative to conventional and robotic surgery.
3 investors
Phantom Space Corporation builds small satellite launch vehicles and satellites, along with its Phantom Cloud data-center constellations, to provide launch and in-space delivery services. The U.S.-controlled company targets customers seeking access to space transportation, satellite manufacturing, and space data.
3 investors
Pharmacelera develops computational chemistry software and services for drug discovery, using proprietary 3D molecular field descriptors, quantum mechanics, and AI to screen ultra-large chemical libraries and identify novel, synthesizable compounds. It serves small biotech companies, big pharma R&D departments, public research institutions, and CROs across stages from target identification to lead optimization.
3 investors
PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address. The company develops first- and best-in-class therapies and originated as a spin-out from the University of Cambridge.
3 investors
Phoenix Molecular Designs (PhoenixMD) is a biotechnology company developing targeted breast cancer therapeutics, including PMD-026, a first-in-class RSK2 inhibitor in Phase 2 clinical trials paired with a companion diagnostic. The company applies medicinal chemistry, computational modeling, and cancer biology to treat breast cancer and other cancers.
3 investors
Phoenix Semiconductor recreates late-generation, legacy, and mature microelectronic components to address the shortage of domestically manufactured legacy chips. It supplies trusted, domestically produced chips to government and commercial partners, including U.S. Department of Defense programs.
3 investors
PhotonPath designs proprietary photonic integrated circuits and ultra-compact optical modules for high-capacity optical networks, AI data centers, and industrial sensing applications. Its products target telecom and optical networking, data center/AI computing, and harsh-environment sensing markets.
3 investors
Photonic is building a commercial-scale, fault-tolerant quantum computer using a unique T-centre qubit technology and Entanglement First distributed architecture designed for unlimited scalability. The company serves enterprises, governments, and academia with quantum computing services, systems, and quantum secure networking capabilities.
3 investors
Phyx44 designs novel proteins engineered for food applications using precision fermentation and protein engineering, serving food manufacturers seeking specific taste, texture, and nutritional functionality. The company produces animal-free proteins through scalable fermentation processes.
3 investors
Moonwalk Biosciences is a life sciences company operating in the biotech sector. This page profiles a member of its leadership team.
3 investors
Plasma Bound, a spin-out of University College Dublin, develops Controlled Polymer Ablation (CPA) surface-engineering technology for bonding lightweight structural assemblies. It serves automotive and aerospace OEMs and Tier 1 manufacturers working with composites and multi-material joints.
3 investors
Point2 Technology develops interconnect chips and cables that use RF transmission over plastic waveguide ("e-Tube") to move data between servers in AI data centers, targeting 400G/800G and terabit-scale links as an alternative to copper and optical connections. It builds low-power interconnect SoCs and retimers aimed at reducing latency, power, and total cost of ownership for data center infrastructure.
3 investors
Polyphron is using AI and automation to produce human tissue at scale, providing ground-truth data for AI biology and developing therapeutics based on immune-compatible iPSC-derived grafts.
3 investors
Porotech develops MicroLED display technology, supplying components and technology consultancy to help partners manufacture microLED displays. It works through partnerships and R&D collaborations in the display hardware and semiconductor space.
3 investors